Drug intelligence / Profile preview

AAV-HO-2

Development stage: Preclinical
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intravenous, Intrathecal, Intracisternal, Intraventricular, Stereotaxic Intraparenchymal, Brain Surgery, Intravitreal, Subretinal, Intramuscular, Intranasal

Overview

AAV-HO-2 is a gene therapy construct designed to deliver the gene for Heme oxygenase-2 (HO-2) using an Adeno-associated virus (AAV) vector. Heme oxygenase-2 (HO-2), also known as HMOX2, is an enzyme that plays a critical role in the degradation of heme into biliverdin, carbon monoxide, and free iron. These products possess important antioxidant and anti-inflammatory properties. The drug is being investigated for its potential to reduce atherosclerosis by preventing inflammation and modulating oxidative stress.

Targets

HMOX2 (Heme oxygenase 2)

Beyond the preview

Go deeper on AAV-HO-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV-HO-2.

Explore the full profile